An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome
Evidence level: guideline; abstract-only
An international guideline from ISHLT, ATS and ERS on the definition, risk factors, diagnosis and management of bronchiolitis obliterans syndrome (BOS).
As of . Primary source: Publisher record via DOI.
Summary
An international committee convened by the International Society for Heart and Lung Transplantation, the American Thoracic Society and the European Respiratory Society produced this guideline on BOS. According to the abstract, it addresses four topics: the definition of BOS, its risk factors, its diagnosis, and its management and prevention. The committee used a systematic evidence search covering publications from 1980 to March 2013 and the GRADE method to develop recommendations. The abstract states that the term BOS should describe a delayed allograft dysfunction with a persistent decline in forced expiratory volume in one second (FEV1) that is not caused by other known and potentially reversible causes. It also states that the diagnosis requires careful exclusion of other post-transplant complications, that the committee made specific recommendations on systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and re-transplantation, and that currently available therapies have not been proven to give significant benefit in the prevention or treatment of BOS. The specific recommendations and their strength were not read for this record. This summary describes the literature and is not medical advice.
Details
- doi
- 10.1183/09031936.00107514
- pmid
- 25359357
- authors
- Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR; ISHLT/ATS/ERS BOS Task Force Committee
- journal
- European Respiratory Journal
- year
- 2014
- volume
- 44
- issue
- 6
- pages
- 1479-1503
Sources and links
- Publisher record via DOI (primary)
- PubMed 25359357
Related
Links from this record
Linked from (derived)
- named in: Azithromycin
- named in: Retransplantation
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- author affiliations
- individual task force members and specific recommendations
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.